OnabotulinumtoxinA in the treatment of neurogenic bladder

Aziz Gulamhusein, Altaf MangeraDepartment of Urology Research, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, United KingdomAbstract: This review examines the evidence for use of onabotulinumtoxinA in the treatment of neurogenic lower urinary tract dysfunction. Since...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gulamhusein A, Mangera A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/fb955cee469248cdbbf9caff8b788a89
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb955cee469248cdbbf9caff8b788a89
record_format	dspace
spelling	oai:doaj.org-article:fb955cee469248cdbbf9caff8b788a892021-12-02T06:07:34ZOnabotulinumtoxinA in the treatment of neurogenic bladder1177-54751177-5491https://doaj.org/article/fb955cee469248cdbbf9caff8b788a892012-08-01T00:00:00Zhttp://www.dovepress.com/onabotulinumtoxina-in-the-treatment-of-neurogenic-bladder-a10842https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Aziz Gulamhusein, Altaf MangeraDepartment of Urology Research, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, United KingdomAbstract: This review examines the evidence for use of onabotulinumtoxinA in the treatment of neurogenic lower urinary tract dysfunction. Since its first use in 1988 to treat detrusor sphincter dyssynergia, use of botulinum toxin has increased in this group of patients. We discuss the mechanism of action, patient selection, dosing, efficacy, and side effect profile of this now licensed treatment option.Keywords: neurogenic bladder, botulinum toxin, onabotulinumtoxinA, neurogenic detrusor overactivity, detrusor sphincter dyssynergiaGulamhusein AMangera ADove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 299-306 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Gulamhusein A Mangera A OnabotulinumtoxinA in the treatment of neurogenic bladder
description	Aziz Gulamhusein, Altaf MangeraDepartment of Urology Research, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, United KingdomAbstract: This review examines the evidence for use of onabotulinumtoxinA in the treatment of neurogenic lower urinary tract dysfunction. Since its first use in 1988 to treat detrusor sphincter dyssynergia, use of botulinum toxin has increased in this group of patients. We discuss the mechanism of action, patient selection, dosing, efficacy, and side effect profile of this now licensed treatment option.Keywords: neurogenic bladder, botulinum toxin, onabotulinumtoxinA, neurogenic detrusor overactivity, detrusor sphincter dyssynergia
format	article
author	Gulamhusein A Mangera A
author_facet	Gulamhusein A Mangera A
author_sort	Gulamhusein A
title	OnabotulinumtoxinA in the treatment of neurogenic bladder
title_short	OnabotulinumtoxinA in the treatment of neurogenic bladder
title_full	OnabotulinumtoxinA in the treatment of neurogenic bladder
title_fullStr	OnabotulinumtoxinA in the treatment of neurogenic bladder
title_full_unstemmed	OnabotulinumtoxinA in the treatment of neurogenic bladder
title_sort	onabotulinumtoxina in the treatment of neurogenic bladder
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/fb955cee469248cdbbf9caff8b788a89
work_keys_str_mv	AT gulamhuseina onabotulinumtoxinainthetreatmentofneurogenicbladder AT mangeraa onabotulinumtoxinainthetreatmentofneurogenicbladder
_version_	1718400088785551360

OnabotulinumtoxinA in the treatment of neurogenic bladder

Ejemplares similares